Company news

Chimeric Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Prospectus

March 17, 2025

Entitlement Offer to raise approximately $3.2 million

March 17, 2025

Reinstatement to Quotation

March 4, 2025

Chimeric announces intention to undertake Entitlement Offer

March 4, 2025

Suspension from Quotation

March 2, 2025

Half Year Report and Appendix 4D 31 December 2024

February 28, 2025

$4.0m Non-Dilutionary Funding

February 27, 2025

Phase 1B CHM CORE-NK trial advances to newly diagnosed AML

December 15, 2024

Chimeric receives $4.17m R&D tax incentive

November 27, 2024

AGM Presentation and CEO Appointment

November 11, 2024

Reinstatement to Official Quotation

October 21, 2024

$5 million Placement to progress CHM CDH17 trial

October 21, 2024

AML patient achieves Complete Response in CHM CORE-NK trial

October 6, 2024

Appendix 4E and Preliminary Final Report

August 30, 2024

First patient dosed in Phase 1/2 trial of CHM CDH17

August 28, 2024

First patient enrolled in CHM CDH17 Phase 1/2 clinical trial

July 22, 2024

Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA

June 4, 2024

Chimeric opens CHM CDH17 Phase 1/2 trial

May 22, 2024

CHM CDH17 Phase 1/2 clinical trial approved for initiation

May 19, 2024

Resignation of CEO and Managing Director

May 1, 2024

Clinical milestones for 2024 & 2023 successes highlighted

March 13, 2024

Half Yearly Report and Accounts

February 28, 2024

1st patient treated in ADVENT-AML Phase 1b clinical trial

February 7, 2024

Placement of Entitlement Offer Shortfall

January 18, 2024

ADVENT-AML Phase 1B clinical trial open to enrolment

January 14, 2024

Chimeric receives $7.36M R&D tax incentive

January 9, 2024

Positive in vitro data for CHM 1301 CAR NK cells

November 22, 2023

1st patient dosed in Phase 1b recurrent glioblastoma trial

November 1, 2023

FDA clearance of IND for CHM 2101

October 30, 2023

Entitlement Offer to raise approximately $10 million

October 24, 2023

New data for Phase 1A CLTX CAR T brain cancer clinical trial

October 22, 2023

Agreement with MD Anderson for Phase 1B CHM 0201 AML study

September 12, 2023

Dosing completion in Phase 1A brain cancer clinical trial

August 28, 2023

Chimeric to receive A$4.4 million introduction fee

August 16, 2023

Positive data - CHM 0301 next-gen armoured NK cell platform

August 14, 2023

CHM secures up to A$12.6m through SPP and placements

June 23, 2023

Share purchase plan completed

June 23, 2023

Launch of new Phase 1B Glioblastoma clinical trial

June 4, 2023

SPP offer documents issued to shareholders

May 22, 2023

Board & management commit to $1M placement and proposed spp

May 15, 2023

New CLTX CAR technology patent protection in India & Israel

April 28, 2023

Phase 1B brain cancer clinical trial approved for initiation

April 25, 2023

CHM 1101 GBM Abstract Accepted for ASCO 2023 Presentation

April 3, 2023

Positive pre-IND meeting with FDA for Phase 1 CAR T study

March 20, 2023

Fourth dose cohort initiated in CHM 1101 Phase 1 trial

March 2, 2023

Appendix 4D and Half Year Report

February 28, 2023

Chimeric receives $3.06M R&D tax incentive

February 14, 2023

Follow up period completed for 3rd cohort in CHM 1101 trial

January 22, 2023

Dosing complete in 3rd cohort of CHM 1101 (CLTX CAR T) trial

December 21, 2022

Exclusive license agreement with CWRU for CORE-NK platform

November 20, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 23 decks. Every deck is listed under its year.